US to halt distribution of flu vaccines with mercury preservative

Published 23/07/2025, 19:12
US to halt distribution of flu vaccines with mercury preservative

Investing.com -- The United States will stop distributing all influenza vaccines containing the mercury-based preservative thimerosal, following a decision by U.S. Health Secretary Robert F. Kennedy Jr.

This policy change comes after a vaccine panel with members selected by Kennedy voted last month to recommend Americans receive seasonal flu shots free from thimerosal, despite decades of scientific evidence showing no safety concerns with the preservative.

During the last flu season, approximately 5% of flu shots administered in the U.S. were from multi-dose vials containing thimerosal, a preservative that had been largely phased out of vaccines decades ago.

The Department of Health and Human Services announced Wednesday that Kennedy had accepted the panel’s recommendation. This decision was made without the typical sign-off from the CDC director, who usually implements such recommendations.

Anti-vaccine groups have long claimed thimerosal is linked to autism and other neurodevelopmental disorders. Kennedy himself authored a book in 2014 advocating for "the immediate removal of mercury" from vaccines.

The FDA states on its website that "there was no evidence that thimerosal in vaccines was dangerous," noting that its previous removal was a precautionary measure to reduce overall mercury exposure in young infants.

One dissenting panelist had argued that the risk of skipping influenza vaccination due to thimerosal concerns outweighed any known risks from the preservative itself.

According to the FDA’s website, affected vaccines include CSL (OTC:CSLLY)’s Afluria, Flucelvax, and Sanofi (NASDAQ:SNY)’s Fluzone, which all contain thimerosal in their multi-dose versions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.